How many patients were in UKPDS 34?

The metformin sub-study randomized 1,704 overweight patients with newly diagnosed type 2 diabetes. Of these, 753 received metformin and 951 received conventional (diet-based) treatment.

What was the primary endpoint of UKPDS 34?

The primary endpoint was any first diabetes-related clinical endpoint, an aggregate of 21 events including myocardial infarction, stroke, amputation, blindness, renal failure, and diabetes-related death.

How much did metformin reduce diabetes complications?

Metformin reduced any diabetes-related endpoint by 32% compared to diet alone (p = 0.002). Diabetes-related death was reduced by 42%, and all-cause mortality by 36%.

Were patients in UKPDS 34 on metformin alone the entire time?

No. By year 9, over half of those randomized to metformin required additional therapy (sulfonylurea or insulin) to maintain glucose targets. The trial tested a "start-with-metformin" strategy, not lifelong monotherapy.

Did UKPDS 34 include normal-weight patients?

No. UKPDS 34 specifically enrolled patients weighing ≥120% of ideal body weight. Normal-weight patients were studied in the broader UKPDS 33 with sulfonylureas and insulin.

What was the metformin dose used in UKPDS 34?

The target dose was 2 to 550 mg/day, given as 850 mg three times daily. This is near the maximum dose used in current clinical practice.

Did metformin's benefits last after the trial ended?

Yes. The UKPDS post-trial monitoring study (2008) showed persistent reductions in MI (33%) and all-cause mortality (27%) a decade after the trial concluded, even though HbA1c differences had equalized within the first year.

Is UKPDS 34 why metformin is first-line for type 2 diabetes?

Yes. UKPDS 34 provided the definitive evidence that metformin reduces cardiovascular events and death in overweight T2D patients without causing weight gain or hypoglycemia. This evidence, combined with low cost and a strong safety profile, underpins every major guideline recommendation.

What was the concern about combining metformin with sulfonylureas?

A subset analysis found a 96% increase in diabetes-related death when metformin was added to sulfonylurea, but this was based on a small subgroup (537 patients) and has not been replicated in subsequent large trials. It is generally considered a chance finding.

How does UKPDS 34 compare to modern cardiovascular outcome trials?

Modern trials (EMPA-REG, LEADER, DAPA-HF) enroll high-risk patients with established cardiovascular disease and test on top of metformin. UKPDS 34 enrolled newly diagnosed, event-free patients and tested metformin itself. The populations and questions differ, making direct comparison inappropriate.

UKPDS 34 Trial: A Plain-English Overview of What It Established

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

| Parameter | Detail | |-----------|--------| | Trial name | UKPDS 34 (United Kingdom Prospective Diabetes Study 34) | | N | 1,704 overweight patients (≥120% ideal body weight) | | Intervention | Metformin (median dose 2 to 550 mg/day) | | Comparator | Conventional treatment (diet alone); secondary comparison with intensive sulfonylurea/insulin | | Duration | Median 10.7 years follow-up | | Primary endpoint | Any diabetes-related clinical endpoint (sudden death, hyperglycemia/hypoglycemia requiring hospital admission, MI, angina, heart failure, stroke, renal failure, amputation, vitreous hemorrhage, retinal photocoagulation, blindness, cataract extraction) | | Key result | 32% risk reduction in any diabetes-related endpoint vs. diet alone (p = 0.002) | | Publication | Lancet 1998; 352: 854-865 |

The Question UKPDS 34 Asked

By the mid-1980s, clinicians knew that high blood glucose damaged organs over time. What they did not know was whether lowering glucose with medication actually prevented those complications, or whether the drugs themselves introduced offsetting harms. For overweight patients specifically, an older trial (the University Group Diabetes Program) had raised alarms about cardiovascular toxicity with oral agents. Metformin, a biguanide available in Europe but not yet approved in the US, had theoretical appeal: it lowered glucose without stimulating insulin secretion and did not cause weight gain. But no long-term randomized trial had tested whether those properties translated into fewer heart attacks, strokes, or deaths.

UKPDS 34 was designed to answer a focused version of this question: in overweight patients with newly diagnosed type 2 diabetes, does a policy of intensive glucose control with metformin reduce clinically important complications compared to conventional dietary management alone?

Who Was Enrolled

Participants were drawn from the broader UKPDS cohort, which recruited 5,102 patients with newly diagnosed T2D from 23 hospital-based clinics across England, Scotland, and Northern Ireland between 1977 and 1991. The UKPDS 34 sub-study included 1,704 patients who met two additional criteria:

Body weight ≥120% of ideal (roughly a BMI above 28 for most participants)
Fasting plasma glucose between 6.1 and 15.0 mmol/L after three months of dietary intervention alone

Enrollment Realities Worth Noting

The trial population was overwhelmingly white (81%), reflecting UK demographics of the recruitment era. Mean age at entry was 53 years. Mean fasting glucose at randomization was 8.1 mmol/L (approximately HbA1c of 7.2%). These patients were early in their disease, had no prior cardiovascular events as an inclusion requirement, and were motivated enough to complete a three-month diet run-in. This matters when generalizing: UKPDS 34 tells us about metformin started early in disease, not about adding metformin to someone already on three drugs with established heart failure.

What They Were Given

The 1,704 overweight patients were randomized in a ratio of roughly 1:2:

753 patients received metformin as first-line intensive therapy (target fasting glucose <6 mmol/L)
951 patients received conventional treatment (diet alone, with pharmacotherapy added only if fasting glucose exceeded 15 mmol/L or symptoms arose)

Metformin was titrated to a maximum of 2 to 550 mg/day (850 mg three times daily). If metformin alone failed to achieve target, sulfonylurea or insulin could be added. In the conventional arm, treatment escalation was delayed until glucose became markedly uncontrolled.

A secondary comparison examined whether metformin performed differently from sulfonylurea or insulin in the parallel intensive-therapy arms of the broader UKPDS (342 patients on metformin vs. 951 on chlorpropamide, glibenclamide, or insulin).

What Was Measured

The primary aggregate endpoint captured the first occurrence of any of 21 predefined diabetes-related clinical events, including myocardial infarction, stroke, amputation, microvascular disease, and sudden death. Secondary endpoints included diabetes-related death, all-cause mortality, and myocardial infarction specifically.

Median follow-up was 10.7 years. Endpoint adjudication was performed by a clinical committee blinded to treatment allocation.

Results in Detail

Metformin vs. Diet Alone (Primary Comparison)

| Endpoint | Metformin (events/1000 patient-years) | Diet alone (events/1000 patient-years) | Risk reduction | p-value | |----------|--------------------------------------|----------------------------------------|----------------|---------| | Any diabetes-related endpoint | 29.8 | 43.3 | 32% | 0.002 | | Diabetes-related death | 7.5 | 12.7 | 42% | 0.017 | | All-cause mortality | 13.5 | 20.6 | 36% | 0.011 | | Myocardial infarction | 11.0 | 18.0 | 39% | 0.01 | | Stroke | 5.0 | 5.2 | 41% (NS after adjustment) | 0.13 |

The numbers needed to treat (NNT) over 10 years: approximately 10 patients treated with metformin to prevent one diabetes-related endpoint, and approximately 14 to prevent one death.

Metformin vs. Sulfonylurea/Insulin Intensive Arms

When metformin was compared head-to-head with the sulfonylurea/insulin intensive groups, metformin produced similar glycemic control (median HbA1c 7.4% in both) but achieved better outcomes:

32% fewer diabetes-related endpoints (p = 0.0023)
42% fewer diabetes-related deaths (p = 0.021)
36% lower all-cause mortality (p = 0.011)

This finding was remarkable. Both strategies lowered glucose by the same amount, yet metformin produced significantly better clinical outcomes. The implication: metformin's benefits were not fully explained by glucose lowering alone.

Weight and Hypoglycemia

Metformin-treated patients gained an average of 1.5 kg less than those on sulfonylureas and 5.8 kg less than those on insulin over the trial period. Major hypoglycemic episodes were also substantially less common with metformin, consistent with its mechanism of reducing hepatic glucose output rather than stimulating pancreatic insulin release.

Methodology Notes Beyond the Abstract

Open-label design. Neither patients nor clinicians were blinded to treatment. This is a legitimate criticism, though endpoint adjudication was blinded and the hard endpoints (death, MI) are less susceptible to ascertainment bias than softer outcomes.

Intention-to-treat with add-on therapy. By year 9, over 50% of the metformin group required additional agents to maintain glycemic targets. The trial analyzed by original randomization, which means metformin's benefit reflects a "start-with-metformin" strategy rather than metformin monotherapy throughout.

The sulfonylurea-combination concern. A subset analysis within UKPDS found that adding metformin to sulfonylurea was associated with a 96% increase in diabetes-related death compared to sulfonylurea alone (p = 0.039). This unexpected signal generated concern but was based on only 537 patients and has not been confirmed in subsequent trials. The authors themselves noted this could be a chance finding.

No placebo control. The comparator was "conventional" dietary treatment, not a matched placebo pill. This design reflects clinical reality but leaves open whether some benefit arose from more frequent clinic visits in the intensive arm.

Limitations the Authors Acknowledged

The trial was powered for the aggregate endpoint, not individual components. The stroke result, for example, did not reach significance.
The overweight-only enrollment limits direct extrapolation to normal-weight T2D patients.
The sulfonylurea-combination signal warranted further study (it was subsequently addressed in the ADOPT and RECORD trials without confirmation of harm).
Recruitment spanned 14 years, meaning early and late enrollees experienced different background care standards.

Long-Term Follow-Up: UKPDS Post-Trial Monitoring

The UKPDS 10-year post-trial follow-up (published 2008) provided critical additional data. After the trial ended in 1997, patients were returned to routine NHS care with no protocol-driven treatment differences. By 2007, HbA1c differences between groups had disappeared within the first year of follow-up. Yet metformin's benefits persisted:

21% reduction in any diabetes-related endpoint (p = 0.01)
33% reduction in MI (p = 0.005)
27% reduction in all-cause mortality (p = 0.002)

This "legacy effect" suggested that early intensive glucose control with metformin provided durable vascular protection extending well beyond the treatment period itself.

What It Means for Clinical Practice Today

UKPDS 34 is the reason every major guideline, from the ADA Standards of Care to NICE and the European Association for the Study of Diabetes, lists metformin as first-line pharmacotherapy for type 2 diabetes. The trial demonstrated three things no other agent had proven at that time:

Reducing glucose with metformin prevents macrovascular complications (heart attacks, cardiovascular death) in addition to microvascular ones.
Metformin achieves this without the weight gain that undermines long-term adherence with insulin and sulfonylureas.
The cardiovascular benefit appears to exceed what glucose lowering alone would predict.

The trial's impact on FDA labeling for metformin was decisive. Prior to UKPDS, metformin's US label focused on glycemic efficacy. After UKPDS 34, the clinical narrative shifted: metformin was not just a glucose-lowering drug but a cardioprotective agent suitable for long-term first-line use.

In the era of SGLT2 inhibitors and GLP-1 receptor agonists (which have their own cardiovascular outcome trials), metformin's position as default first-line therapy has been questioned but not displaced. Its cost (under $4/month generic), safety record spanning decades, and the UKPDS evidence base maintain its guideline primacy.

Frequently asked questions

›

References

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865. PubMed
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589. PubMed
American Diabetes Association. Standards of Care in Diabetes, 2024. Diabetes Care. 2024;47(Suppl 1):S158-S178. ADA
FDA. Metformin hydrochloride prescribing information. FDA Label
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853. PubMed